Events | Viralgen

Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.

VIRALGEN VECTOR CORE

CLINICAL FACILITY

Paseo Mikeletegi, 83
Parque Científico y Tecnológico de Gipuzkoa,
20009 San Sebastián, Spain

COMPANY HEADQUARTERS &
COMMERCIAL FACILITY

Paseo Mikeletegi, 8
Parque Científico y Tecnológico de Gipuzkoa,
20009 San Sebastián, Spain

VIRALGEN VECTOR CORE

CLINICAL FACILITY

Paseo Mikeletegi, 83
Parque Científico y Tecnológico de Gipuzkoa,
20009 San Sebastián, Spain

COMPANY HEADQUARTERS &
COMMERCIAL FACILITY

Paseo Mikeletegi, 8
Parque Científico y Tecnológico de Gipuzkoa,
20009 San Sebastián, Spain

Viralgen, founded in 2017 as a subsidiary of AskBio within the Bayer AG group, is a premier CDMO specializing in AAV-based gene therapies delivering end-to-end support from construct optimization and plasmid DNA production through large-scale clinical and commercial manufacturing. Leveraging the Aava™ manufacturing platform built upon its proprietary Pro10™ suspension cell line, Viralgen achieves industry-leading, high-yield, scalable manufacturing across all AAV serotypes, in the world’s largest AAV-dedicated facility, to help clients scale efficiently, optimize cost of goods, and mitigate risk.

© VIRALGEN 2026. All rights reserved.

Please review the following rules: